Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Altuviiio May See Rapid Uptake Upon European Approval In Hemophilia A

Pediatric Data Clears Path For EMA Filing

Executive Summary

Sanofi announced results from its XTEND-Kids trial, clearing the last requirement before an anticipated second half filing for Altuviiio’s approval with the EMA.

You may also be interested in...



Sanofi’s Altuviiio Set To Reenergize Factor VIII Space

The once-weekly Factor VIII replacement therapy for hemophilia A, newly approved by the US FDA, appears well positioned to compete with Roche’s blockbuster Hemlibra.

Sanofi Looks To Dominate $5bn Hemophilia A Factor Market After Trial Success

Phase III success for efanesoctocog alfa sets up a filing in the near future, and a chance to seize market share from existing Factor VIII products, as well as Roche’s Hemlibra.

Novartis Expands In Protein Degradation, Complements Radioligand Platform With Arvinas Deal

Deal Snapshot: The company told Scrip that part of why it licensed Arvinas’s ARV-766 and took over AR-V7 was to complement its radioligand therapy platform in prostate cancer.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC147996

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel